20 November 2017 (Monday) - The Oncologist Newsletter

The Oncologist Newsletter appeared in my in-box this morning:

Featured Article First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer Maria Vittoria Dieci et al. Multiple risk factors for both venous thromboembolism (VTE) and early mortality in patients with lung cancer receiving systemic chemotherapy should guide best practice by better informing clinical evaluation and treatment decision‐making. The Khorana risk score is of value in assessing the risk of early all‐cause mortality along with other clinical parameters in patients with lung cancer receiving systemic therapy. Further study is needed to fully evaluate the validity of the risk score in predicting the risk of VTE in the modern era of lung cancer therapy. In the News New Director of Cancer Research UK Cambridge Institute Announced Pancreatic Cancer: Is an 'Electronic Nose' the Answer to Achieving Early Diagnosis? British Researchers Get £1.5M Boost for Bowel Cancer Research

CME Activities Perceptions of Cancer Care and Clinical Trials in the Black Community: Implications for Care Coordination Between Oncology and Primary Care Teams Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer (PRROC) - the GCIG Symptom Benefit Study ADVERTISEMENT

Special Report from the 2017 ESMO Annual Meeting At the European Society for Medical Oncology (ESMO) 2017 Congress, held September 8-12, 2017, in Madrid, Spain, the theme was "integrating science into oncology for a better patient outcome." In this ESMO 2017 Special Report, The Oncologist focuses on new research on the use of prognostic and predictive biomarkers in the individualized management of patients with colorectal cancer. Clinical Trial Results A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial Lessons Learned >The addition of the heat shock protein 27 (Hsp27)‐targeting antisense oligonucleotide, apatorsen, to a standard first‐line chemotherapy regimen did not result in improved survival in unselected patients with metastatic pancreatic cancer. > Findings from this trial hint at the possible prognostic and predictive value of serum Hsp27 that may warrant further investigation.

Conference Perspectives: Lessons Learned Evolving Standards in Colorectal Cancer: Case-Based Insights from ESMO 2017 David P. Ryan, MD, explores new standards of care in advanced and metastatic colorectal cancer (mCRC). 0.5 AMA PRA Category 1 Credits™ Begin Activity